Dr. Yardley on BOLERO-2 Results for HR+ Breast Cancer

Denise A. Yardley, MD
Published: Tuesday, Nov 28, 2017



Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

According to Yardley, hormone resistance is an important area for patients with HR-positive breast cancer. Data from the BOLERO-2 study made the combination of everolimus (Afinitor) and exemestane a standard of care for patients who were failing endocrine therapy.

Additionally, CDK4/6 inhibitors have rolled out in advanced patients in the second-line setting, explains Yardley.
 
SELECTED
LANGUAGE


Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

According to Yardley, hormone resistance is an important area for patients with HR-positive breast cancer. Data from the BOLERO-2 study made the combination of everolimus (Afinitor) and exemestane a standard of care for patients who were failing endocrine therapy.

Additionally, CDK4/6 inhibitors have rolled out in advanced patients in the second-line setting, explains Yardley.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x